Search results
Found 547 matches for
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
"We loved being in the BioEscalator, and part of the community, and the support and flexibility from the BioEscalator team was invaluable."
Hollie Coe, Base Genomics (now Exact Sciences Innovation)
"The high-quality facilities, resources and support to grow a company were invaluable."
Tim Funnell, MiroBio (now Gilead)
